Finally, clinical studies combined GR-MD-02 with other therapeutic molecules, such as ipilimumab (anti-CTLA4 antibody) in metastatic melanoma patients (NCT02117362) and pembrolizumab (anti-PD-1 antibody) in patients with metastatic melanoma, non-small cell lung cancer, and head and neck cancer (NCT02575404). Here, CTLA4 is linked to metastatic melanoma.